[Method of dialysis therapy and selected markers of oxidative stress and endothelial injury in patients with chronic renal failure].
Cardiovascular diseases (CVD), being mostly a clinical manifestation of atherosclerosis, are the main cause of mortality in patients with chronic renal failure (CRF). It is now generally accepted that the first step in atherosclerosis is endothelial dysfunction. Recently, oxidative stress (SOX) has been implicated as an important etiologic factor in atherosclerosis and vascular dysfunction both in general and uremic populations. The aim of the present study was to establish the effect of two different method of dialysis therapy: hemodialysis (HD) and continuous peritoneal dialysis (CAPD) on the markers of SOX: lipid peroxides, Cu/Zn superoxide dismutase (Cu/Zn SOD) and autoantibodies against oxidized LDL (OxLDL-Ab), and endothelial injury: antigen of the von Willebrand factor (vWF : Ag), soluble thrombomodulin (TM) and tissue factor pathway inhibitor (TFPI) in 43 patients with CRF. Compared with the control subjects, patients with CRF showed a significant increase in plasma concentrations of Cu/Zn SOD, which was more elevated in HD than in CAPD group. The lipid peroxide levels were increased only in the post-HD samples, whereas OxLDL-Ab were more elevated in HD than in CAPD group. Markers of endothelial injury were significantly higher in dialyzed patients relative to controls, and were positively correlated themselves as well as with Cu/Zn SOD levels. The patients on HD and CAPD are exposed to increased SOX as well as to endothelial injury. The association between Cu/Zn SOD and the endothelial injury markers suggests the possible effect of oxidative stress on endothelial dysfunction in CRF patients.
Pawlak
Krystyna
K
Klinika Nefrologii i Transplantologii z Ośrodkiem Dializ AM w Białymstoku. krvstvnaoawlak@poczta.onet.pl
Pawlak
Dariusz
D
Myśliwiec
Michał
M
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood*; D004730:Endothelium, Vascular / Q000293:injuries* / Q000378:metabolism; D005260:Female; D017583:Hemodiafiltration / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy*; D008054:Lipid Peroxides / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D013482:Superoxide Dismutase / Q000097:blood; D018180:Thrombomodulin / Q000097:blood; D014841:von Willebrand Factor / Q000378:metabolism
D015415:Biomarkers; D008054:Lipid Peroxides; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D018180:Thrombomodulin; C051928:lipoprotein-associated coagulation inhibitor; C099252:oxidized low density lipoprotein; D014841:von Willebrand Factor; D013482:Superoxide Dismutase